AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11166518
Drug: Apomorphine (APO),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (APO), 0.01 mg/kg
Trial: 6149592
Drug: Antipsychotic drug
RxNorm normalized name: antipsychotic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drug treatment
Trial: 9154767
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg orally once per day for four weeks)
Trial: 8227504
Drug: Clinician administered
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician administered treatment
Trial: 25917060
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg)
Trial: 24602844
Drug: Delayed antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antiretroviral treatment
Trial: 17766190
Drug: Intravenous meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous meropenem (120 mg/kg/day) and intravenous tobramycin (9-12 mg/kg/day)
Trial: 17766190
Drug: Intravenous ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ceftazidime (200-400 mg/kg/day) and intravenous tobramycin (9-12 mg/kg/day)
Trial: 6711270
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of 1% mepivacaine with adrenaline 1:200,000
Trial: 6711270
Drug: 60 ml
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml of 1% mepivacaine with adrenaline 1:200,000
Trial: 29855172
Drug: ABT-122 120
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 120 mg every other week
Trial: 29855172
Drug: ABT-122 120
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 120 mg every week
Trial: 17488511
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) in addition to managed care, consisting of three to six individual sessions of 30 minutes each.
Trial: 17488511
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) in addition to managed care.
Trial: 2707527
Drug: Hydrocortisone intravenous
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone intravenous (HC i.v.: 100 mg)
Trial: 2707527
Drug: Hydrocortisone local
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone local (HC L: 100 mg)
Trial: 2707527
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA: 4 g)
Trial: 8572357
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg‐1 given 5 min before desflurane increase
Trial: 16000582
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of 100 mg/m2 paclitaxel (Taxol)
Trial: 16000582
Drug: 3-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hour infusion of 100 mg/m2 paclitaxel (Taxol)
Trial: 2071554
Drug: Phenytoin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (100 mg po bid for adults and 50 mg po bid for children)
Trial: 26650493
Drug: Supraperiosteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraperiosteal injection
Trial: 25786679
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 20 ml bupivacaine 0.25% with adrenaline 5 μg/ml bilaterally
Trial: 22996850
Drug: Weekly information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly information on general health (control group)
Trial: 17300719
Drug: Artemisinin compounds
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin compounds
Trial: 12871538
Drug: Oral ximelagatran
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ximelagatran (24, 36, 48 or 60 mg twice daily)
Trial: 12871538
Drug: Low‐molecular‐weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Trial: 12844328
Drug: Oral ximelagatran
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ximelagatran
Trial: 12871538
Drug: Oral ximelagatran
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ximelagatran and Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Trial: 8542165
Drug: Low-dose and
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose and high-dose inhaled terbutaline
Trial: 2669441
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg moclobemide
Trial: 1792931
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg isocarboxazide
Trial: 6359972
Drug: Bupivacaine-fentanyl combination
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bupivacaine-fentanyl combination (0.5% bupivacaine 1.06 ml per metamer + fentanyl 1.70 +/- 0.09 micrograms X kg‐1)
Trial: 6359972
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (0.5% bupivacaine 1.18 ml per metamer)
Trial: 27207001
Drug: AMSA nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMSA nerve block injection at the most common injection site with 3% mepivacaine solution
Trial: 27207001
Drug: AMSA nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMSA nerve block injection at the anterior injection site with 3% mepivacaine solution
Trial: 20449526
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy combined with beclomethasone diproprionate through exclusively nasal inhalation (BDT group)
Trial: 20449526
Drug: Only beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only beclomethasone diproprionate through exclusively nasal inhalation (BDI group)
Trial: 7755068
Drug: Erythromycin (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (333 mg three times a day)
Trial: 436200
Drug: Hydralazine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (100 mg) and Isosorbide Dinitrate (40 mg)
Trial: 18346063
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment with 5-minute application of liposomal lidocaine cream
Trial: 6189335
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate (active corticosteroid preparation)
Trial: 6189335
Drug: Placebo (basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (basal formulation only)
Trial: 22901620
Drug: Alternate-week dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alternate-week dexamethasone (10 mg/m² per day on days 0-6 and 14-20)
Trial: 22901620
Drug: Continuous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous dexamethasone (10 mg/m² per day on days 0-20)
Trial: 12506171
Drug: FU/LV +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU/LV + low‐dose bevacizumab (5 mg/kg every 2 weeks)
Trial: 12506171
Drug: FU/LV +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU/LV + high‐dose bevacizumab (10 mg/kg every 2 weeks)
Trial: 8137694
Drug: Enhanced preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced preparation intervention (written instructions, reminder to post instructions in the bathroom, toilet seat cover with reminder, nurse-initiated telephone call)
Trial: 8137694
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation intervention (written instructions, telephone number for questions)
Trial: 3627588
Drug: 16 dimethyl
RxNorm normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 16 dimethyl prostaglandin E2 (PGE2) vaginal suppository
Trial: 25087085
Drug: Continuous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous furosemide infusion (cIV)
Trial: 19231632
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg (dose increase for patients with platelet counts <50,000 after 3 weeks)
Trial: 30060980
Drug: AREDS2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AREDS2 treatment assignment
Trial: 22006541
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg GS-9450
Trial: 22006541
Drug: GS-9450 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GS-9450 treatment groups
Trial: 17109733
Drug: Daclizumab (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (single-dose administration)
Trial: 15800130
Drug: Control dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control dialysate (G)
Trial: 12468113
Drug: GHRH administered
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administered intravenously (50 microg)
Trial: 12468113
Drug: GHRH administered
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administered intranasally (300 microg)
Trial: 20207062
Drug: IN ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN ketorolac 31.5 mg
Trial: 17977171
Drug: 0.5‐mg dinoprostone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mg dinoprostone intracervical (IC) gel
Trial: 22605570
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg twice a day)
Trial: 934534
Drug: Reserpine (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine (0.20 mg administered intravenously in standardized cycles of twenty administrations)
Trial: 30735073
Drug: EPA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (3 g/day)
Trial: 31192968
Drug: PASCAL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PASCAL treatment
Trial: 28929698
Drug: S. flavescens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. flavescens gel (test group, 40 cases)
Trial: 28929698
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant interferon α‐2b gel (control group, 40 cases)
Trial: 28929698
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of S. flavescens gel and human recombinant interferon α‐2b gel (combined application group, 40 cases)
Trial: 25163441
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg alcohol (mean peak blood alcohol content of 0.051%)
Trial: 25163441
Drug: Energy drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drink alone (250 ml)
Trial: 23032549
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (200,000 IU initial dose, 200,000 IU one month later, then 100,000 IU monthly for 18 months)
Trial: 23032549
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical dosing regimen to vitamin D3)
Trial: 16787687
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb)
Trial: 16787687
Drug: vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC)
Trial: 23336294
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg once daily started 6-8 hours after surgery)
Trial: 9710030
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (500 mg once a day for 5 days with a 10-day tapering period)
Trial: 25186785
Drug: Detectable drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable drug concentrations
Trial: 9550459
Drug: Nasoenteral tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasoenteral tube feedings at 125 cc/hour over 11 hours each night in addition to standard post-operative nutritional care
Trial: 11519638
Drug: Nicotine treatment
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine treatment
Trial: 2541121
Drug: WR-2721 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR-2721 and cis-platinum (150 mg/m2)
Trial: 2541121
Drug: WR-2721 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR-2721 and cis-platinum (120 mg/m2)
Trial: 6402
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution 0.5%
Trial: 6402
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution 1.0%
Trial: 6402
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution 1.5%
Trial: 6402
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution (all concentrations)
Trial: 25962601
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of adalimumab (ADA) after 12 months of treatment
Trial: 17855815
Drug: Early hemodynamic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early hemodynamic optimization strategies (early goal-directed therapy)
Trial: 14713799
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release ciprofloxacin 1,000 mg once daily
Trial: 14713799
Drug: Conventional ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional ciprofloxacin 500 mg twice daily
Trial: 8632216
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin A supplements
Trial: 1575179
Drug: Duteplase (rt-PA)
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duteplase (rt-PA) maintenance infusion at doses of 0.012, 0.024, 0.036, 0.048 MIU/kg/hour for 9 to 21 hours
Trial: 1575179
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of rt-PA administered
Trial: 26824595
Drug: Acetazolamide administration
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide administration and prone positioning for 10 days
Trial: 9151795
Drug: cM‐T412 (chimeric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cM‐T412 (chimeric CD4 monoclonal antibody)
Trial: 2655367
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of intravenous regional analgesia technique (removal of excess local anaesthetic solution)
Trial: 2655367
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of excess local anaesthetic agent after 15 min
Trial: 1108754
Drug: Loperamide 2
RxNorm normalized name: loperamide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 2 mg capsules, optimal daily dose ranged from two to seven capsules.
Trial: 1108754
Drug: Loperamide 2
RxNorm normalized name: loperamide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 2 mg capsules (in double-blind placebo-controlled trial for ten days or until relapse).
Trial: 1108754
Drug: Loperamide 2
RxNorm normalized name: loperamide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 2 mg capsules.
Trial: 28722611
Drug: Ferroquine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferroquine + Artesunate (200 mg/day)
Trial: 28722611
Drug: Amodiaquine (612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (612 mg/day) + Artesunate (200 mg/day)
Trial: 16924799
Drug: SCENAR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCENAR therapy
Trial: 15180356
Drug: Mizolastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (10 mg)
Trial: 14696020
Drug: Fexofenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (120 mg)
Trial: 12903420
Drug: Alanyl‐glutamine [0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanyl‐glutamine [0.5 g/(kg.d)]
Trial: 12903420
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (isocaloric parenteral nutrition without glutamine)
Trial: 9350072
Drug: Metformin up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin up to 2000 mg day-1
Trial: 31698478
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.035 mg/kg)
Trial: 29856175
Drug: Blueberry juice
RxNorm normalized name: lowbush blueberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry juice (500 mL/day for 14 days preoperatively)
Trial: 17199952
Drug: Amiodarone 100
RxNorm normalized name: amiodarone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 100 mg daily (Group B)
Trial: 14618939
Drug: DEAE-Dextran at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEAE-Dextran at 2.5 g/day
Trial: 7627695
Drug: Probucol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (0.5 g BID) added to diet and cholestyramine (8 g BID)
Trial: 7627695
Drug: Probucol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (0.5 g BID)
Trial: 2035782
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% amethocaine hydrochloride
Trial: 30089792
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of APL daily containing 970 mg of dihydromyricetin
Trial: 30089792
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g of APL daily without dihydromyricetin)
Trial: 28610718
Drug: Echinacea purpurea-derived
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea-derived alkylamides (Ec. extract) cream
Trial: 12586132
Drug: Clivarin (4200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clivarin (4200 U once daily subcutaneous)
Trial: 1469
Drug: Community alternative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community alternative treatment
Trial: 7022244
Drug: Antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithymocyte globulin (ATG) administration
Trial: 10549062
Drug: Placebo, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one similar capsule b.i.d. for 21 days
Trial: 7796625
Drug: Cold crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold crystalloid cardioplegia (St. Thomas Hospital solution) with hypothermic CPB
Trial: 30785826
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of epirubicin (E) 90 mg/m2 and cyclophosphamide (C) 600 mg/m2 followed by four cycles of docetaxel (T) 100 mg/m2
Trial: 30785826
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of docetaxel (T) 75 mg/m2 and cyclophosphamide (C) 600 mg/m2
Trial: 15318308
Drug: ml/kg RBW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ml/kg RBW method
Trial: 15318308
Drug: ml/kg OBW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ml/kg OBW method